Browse the evidence

A bimodal GLP-1/MK-801 conjugate produces synergistic weight loss and metabolic improvements in diet-induced obese rodents by targeting NMDA receptors in GLP-1-expressing brain regions, while mitigating the adverse behavioral and physiological effects of MK-801 monotherapy.

This research describes a new experimental drug that combines two mechanisms to treat obesity in animals. It works by targeting specific brain cells to reduce food intake and increase energy expenditure without the side effects of older drugs. This is not yet available for humans.

Hepatic overexpression of the enzyme ALOXE3 enhances whole-body insulin sensitivity and reduces weight gain by generating the PPARγ ligand 12-KETE.

This research identifies ALOXE3 as a key enzyme induced by fasting that improves insulin sensitivity by activating PPARγ. While direct supplementation with ALOXE3 is not currently available, the findings suggest that strategies inducing this enzyme, such as fasting or specific glucose transporter blockers (like trehalose), may offer metabolic benefits. Current clinical application is limited as genetic therapy is not yet optimized for polygenic diseases like obesity.

In real-world outpatient settings for Type 2 Diabetes, pharmacological management of blood pressure, HbA1c, and LDL cholesterol achieves target control in only a minority of patients, with combined adequate control of all three factors occurring in just 16.4% of cases.

If you have Type 2 Diabetes, having prescriptions for blood pressure, sugar, and cholesterol medication does not guarantee your body is responding correctly. In this study, only 16% of patients had all three numbers in the safe zone. You must actively monitor your HbA1c, LDL, and Blood Pressure, not just fill your prescriptions. If your numbers are not at target, discuss intensifying or changing your therapy with your doctor.

Sibutramine increases the risk of nonfatal cardiovascular events (myocardial infarction and stroke) in patients with pre-existing cardiovascular disease or type 2 diabetes with additional risk factors, leading to its contraindication in these populations.

If you have heart disease, a history of stroke, or diabetes combined with other heart risks (like high blood pressure or smoking), sibutramine is not safe for you. It increases your chance of having a heart attack or stroke. Do not use this medication if you fall into these categories; consult your doctor for safer alternatives.

Traditional weight management strategies, including lifestyle interventions and metabolic and bariatric surgery (MBS), are generally ineffective for reducing hyperphagia in patients with rare MC4R pathway diseases because they do not address the underlying pathophysiology.

For patients with rare genetic obesity (POMC, LEPR, BBS, etc.), standard diets, exercise programs, and even weight-loss surgery often fail to control the insatiable hunger (hyperphagia). This is not a failure of willpower but a failure of the treatment to address the specific brain signaling defect. Recognizing this can reduce caregiver guilt and shift focus toward seeking targeted genetic therapies.

Selective activation of Gs signaling in enteroendocrine K cells increases endogenous GIP secretion, which improves glucose tolerance in obese and diabetic mouse models.

This research suggests that therapies targeting the specific signaling pathways (Gs) in gut K cells to boost natural GIP production could be a viable strategy for managing obesity and Type 2 Diabetes, potentially offering better glucose control than current approaches that rely on external hormone administration.

Other GLP-1 receptor agonists and SGLT2 inhibitors, including semaglutide, dulaglutide, and canagliflozin, did not demonstrate a statistically significant elevation in gynecologic tumor risk compared to controls.

If you are taking other GLP-1 receptor agonists (like semaglutide or dulaglutide) or SGLT2 inhibitors (like canagliflozin or empagliflozin), this network meta-analysis did not find a statistically significant increase in gynecologic tumor risk for these agents. However, the authors note that more data is needed to confirm whether the association with tirzepatide is causal.

GLP-1 receptor agonists (GLP-1 RAs) are not cost-effective at current prices, requiring significant price reductions to meet standard willingness-to-pay thresholds.

GLP-1 RAs are clinically effective but not cost-effective at current prices. They should be used selectively (e.g., for those who cannot undergo surgery) and only if pricing aligns with their health benefits.

Peripheral GLP-1 signaling is not essential for long-term energy balance or bodyweight regulation in humans or rodents, as evidenced by normal body weight in GLP-1R knockout mice and lack of effect from peripheral antagonism.

Your body's natural production of GLP-1 in the gut does not significantly control your long-term weight. This is why lifestyle changes alone often fail to sustain weight loss, and why pharmacologic doses that strongly activate brain receptors are needed for significant weight reduction.

The presence of muricholic acids (MCAs) in mice is critical for their high basal bile acid and cholesterol synthesis and low serum LDL levels; genetic elimination of MCAs in mice results in a human-like metabolic phenotype characterized by reduced synthesis and increased LDL cholesterol.

This research highlights that mice and humans regulate cholesterol and bile acids differently due to specific bile acid types (MCAs). For humans, this implies that therapies targeting bile acid metabolism must account for species-specific pathways, as mouse models lacking these pathways (KO mice) better mimic human metabolic responses.

Bile duct ligation (BDL) paradoxically stimulates bile acid synthesis in wild-type mice but not in mice lacking MCAs, indicating that MCAs are required for this paradoxical response.

This finding suggests that the body's response to bile flow obstruction (cholestasis) is heavily influenced by the type of bile acids present. In humans, where MCAs are not produced, this paradoxical response does not occur, highlighting a key difference in how we might treat cholestatic diseases compared to rodent models.

Gut-derived GLP-1 is not essential for the control of food intake or body weight in mice under normal conditions.

While gut health is important, the brain's response to GLP-1 is more critical for regulating food intake. GLP-1 medications work by acting on the brain, not just the gut.

Hypothalamic Glp1r-expressing cells are predominantly neuronal and localized to arterial vascular beds, whereas Gipr-expressing cells are predominantly non-neuronal (oligodendrocytes and pericytes) and localized to venous vascular beds.

This research suggests that GLP-1 and GIP drugs work through different pathways in the brain. GLP-1 primarily targets neurons and arterial blood vessels, while GIP targets support cells (oligodendrocytes) and venous blood vessels. This distinct localization may explain why combining them (dual agonism) is more effective for weight loss than using GLP-1 alone.

High-calorie diets uncouple hypothalamic oxytocin (PVNOT) neurons from gut-derived CCK signaling via increased kappa-opioid tone and reduced CCKAR expression, rendering CCK ineffective at suppressing food intake.

If you are eating a high-calorie, high-fat/sugar diet, your body's natural ability to feel full from gut hormones like CCK is biologically suppressed. This is not a failure of willpower but a broken signal. To regain control, you must address the diet composition to potentially restore this pathway, or utilize interventions (like specific pharmacological combinations of OT and CCKAR agonists shown in the study) that bypass this block.

Selective activation of oxytocin-expressing PVN neurons (PVNOT) restores the ability of cholecystokinin (CCK) to suppress food intake in diet-induced obese mice.

This finding suggests that simply taking CCK might not work for obese individuals because their oxytocin pathway is disconnected. Future therapies might need to combine CCK with agents that activate oxytocin neurons or bypass this block to be effective.

Pharmacological inhibition of central aPKC activity acutely increases food intake and worsens glucose tolerance in chow-fed rodents.

Blocking a specific brain enzyme (aPKC) can cause immediate overeating and poor blood sugar control, even in lean animals. This underscores the importance of this enzyme in regulating hunger and metabolism.

Deletion of PKC-l in POMC neurons causes central leptin resistance, characterized by reduced melanocortin content and impaired leptin-induced neuronal activation.

Leptin resistance can be caused by defects in the downstream signaling of POMC neurons, specifically involving aPKC. This leads to reduced production of satiety signals (melanocortin), contributing to obesity.

GLP-1 receptor internalization is arrestin-independent and relies on a dual mechanism involving Gs/Gi/o protein activation, GRK phosphorylation, and both clathrin- and caveolae-mediated endocytosis.

This research clarifies that GLP-1 drugs work by engaging specific cellular recycling pathways (clathrin and caveolae) rather than the arrestin pathway. This mechanistic insight aids in designing drugs with optimized duration and fewer side effects, though it does not change immediate patient behavior.

Intensive lifestyle intervention (diet and exercise) does not significantly alter the rate of kidney function decline (eGFR slope) over 10 years in patients with type 2 diabetes and preserved baseline kidney function compared to usual care.

If you have type 2 diabetes and normal kidney function, an intensive lifestyle program focusing on weight loss and 175 minutes of weekly exercise will not significantly change the *rate* at which your kidney function declines over 10 years compared to standard diabetes care. However, it may help maintain a slightly higher average kidney function level, especially if your baseline function is already slightly reduced (eGFR <80). Focus on the overall health benefits rather than expecting a specific kidney outcome.

Circulating IGF-1 concentrations are not associated with all-cause, cardiovascular disease, or cancer-related mortality risk.

There is no evidence from this study that your natural IGF-1 levels predict your risk of death from cancer, heart disease, or other causes. You do not need to try to manipulate IGF-1 levels for longevity based on this data.

Loss-of-function mutations in the myostatin (MSTN) gene cause excessive skeletal muscle growth (hypertrophy) and increased strength by removing the natural inhibition on muscle development.

This paper describes a rare genetic condition (myostatin deficiency) that causes massive muscle growth. For the average person, this is not a viable or safe intervention. However, understanding that myostatin limits growth suggests that therapies blocking it (under medical supervision) might help those with muscle-wasting diseases, but it is not a recommendation for healthy individuals seeking hypertrophy.

Semaglutide does not significantly impact renal outcomes, including nephrolithiasis, acute kidney injury, or chronic kidney disease, in patients with overweight or obesity.

If you are using semaglutide for weight management or cardiovascular risk reduction, do not expect it to protect your kidneys. This meta-analysis found no significant impact on renal outcomes like kidney stones or acute kidney injury in overweight or obese patients.

Pharmacological inhibition of Complement C3 using AMY-101 improves healthspan, metabolic fitness, and reduces inflammaging in aged mice.

In aged mice, weekly injections of a C3 inhibitor (AMY-101) improved metabolic health and physical function. This suggests that targeting the complement system could be a viable strategy to combat age-related decline, potentially mimicking the benefits of caloric restriction.

Age-associated elevation of C3a in visceral adipose tissue (VAT) is primarily driven by adipose tissue macrophages (ATMs) via an autocrine ERK-dependent signaling loop.

In aging, fat tissue (specifically visceral fat) becomes a source of inflammation due to immune cells (macrophages) producing complement proteins like C3a. This process is driven by specific signaling pathways within these cells.